Skip to main content

Swiss Federal Institute of Technology Lab to Use VisEn's Fluorescence Probes

NEW YORK (GenomeWeb News) – VisEn Medical today said that the Swiss Federal Institute of Technology will use its portfolio of in vivo fluorescence probes and fluorescence molecular tomography imaging system in its molecular imaging programs.
 
VisEn said its technologies are designed to identify, characterize, and quantify a range of biological phenomena in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular disease, and bone disease.
 
The technology will be used in the lab of Markus Rudin, whom the company has appointed to its scientific advisory board.
 
Rudin is a professor of molecular imaging and functional pharmacology at the Swiss Federal Institute of Technology and the University of Zürich. He has been the head of imaging technologies at Novartis.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.